Last updated on August 2019

An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease


Brief description of study

This study seeks to evaluate the safety and efficacy of brazikumab versus placebo (Stage I) and versus an active comparator (Stage 2) in participants with moderately to severely active CD and will include assessments of clinical response as demonstrated by improvement of symptoms and colonic mucosal appearance as observed on endoscopy

Clinical Study Identifier: NCT03759288

Find a site near you

Start Over

Trialspark

Astoria, NY United States
4.14miles
  Connect »

Trialspark

New York, NY United States
7.01miles
  Connect »

Manhattan Medical Research

New York, NY United States
7.01miles
  Connect »

Trialspark, Inc.

New York, NY United States
7.88miles
  Connect »